Feb 22, 2022 7:00 am EST Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
Feb 9, 2022 4:05 pm EST Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Nov 12, 2021 4:05 pm EST Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
Oct 13, 2021 8:10 am EDT Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
Oct 12, 2021 4:05 pm EDT Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
Sep 22, 2021 4:05 pm EDT Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
Sep 15, 2021 4:56 pm EDT Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
Sep 9, 2021 4:05 pm EDT Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
Aug 10, 2021 7:00 am EDT Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
